Rhythm Pharmaceuticals Stock Soars After Impressive Q1 Earnings Report
Rhythm Pharmaceuticals (RYTM +7.86%) made a significant impression on investors on Tuesday, with its stock closing nearly 8% higher in value. The commercial-stage biotech company’s quarterly earnings report was well-received, thanks to the impressive performance of its weight-loss drug Imcivree.
Imcivree Drives Revenue Growth
Rhythm reported its first-quarter results, with revenue nearly doubling year over year to $60.1 million, compared to $32.7 million in the same quarter of 2025. This exceeded the consensus analyst estimate of $57 million. The company’s net loss under generally accepted accounting practices (GAAP) deepened to $56.7 million, or $0.83 per share, but was slightly better than the average pundit projection of $0.86.
The increase in revenue was largely driven by Imcivree, which received approval for a new indication (acquired hypothalamic obesity, or HO) in March. The company reported a sharp increase in selling, general, and administrative expenses, which is typical after a new approval. However, the investment seems to be paying off, with over 150 patient start forms received for Imcivree to treat HO within six weeks of the FDA’s approval.
International Success
In addition to the impressive performance of Imcivree, Rhythm reported a sales spike in Europe, with revenue jumping 27% quarter over quarter. This was driven by strong demand in major markets like Germany and France. The company’s pipeline, centered on the continued development of Imcivree for other indications, also provides a positive outlook for the future.
Overall, Rhythm Pharmaceuticals’ Q1 earnings report was a resounding success, with Imcivree driving revenue growth and international sales on the rise. The company’s flexibility and durability, demonstrated by Imcivree’s first FDA approval in 2020, load it with good potential for the future. The bullish reaction from investors was entirely appropriate, given the promising results.
As the company continues to develop Imcivree for new indications, investors will be eagerly watching for further updates. With its strong performance in the first quarter, Rhythm Pharmaceuticals is well-positioned for continued growth and success in the biotech industry.
